SynthesisFrontiers in pharmacology2026
Preclinical effects of naringin on bone outcomes in animal models of osteoporosis: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Naringin, a flavanone glycoside derived from citrus plants and other botanical sources, has shown potential skeletal protective effects in preclinical studies. However, quantitative evidence regarding its effects across different osteoporosis models and skeletal outcomes remains limited. Methods: A systematic review and meta-analysis of controlled preclinical animal studies evaluating naringin in osteoporosis-related bone-loss models was conducted. Five databases were searched from January 2010 to May 2026. Standardised mean differences (SMDs) expressed as Hedges' Results: Naringin was associated with higher bone mineral density (BMD; (SMD = 2.30, 95% CI 1.88-2.72), bone volume fraction (BV/TV; SMD = 3.36, 95% CI 2.17-4.55), trabecular thickness (Tb.Th; SMD = 2.35, 95% CI 1.49-3.21), trabecular number (Tb.N; SMD = 3.30, 95% CI 1.98-4.61), and lower trabecular separation (Tb.Sp; SMD = -2.92, 95% CI -4.01 to -1.83). Favourable pooled effects were also observed for several bone turnover markers. Prediction intervals excluded the null for BMD and C-terminal telopeptide of type I collagen (CTX-1) but crossed the null for most other outcomes. Sensitivity analyses generally preserved the direction of the pooled effects, although potential small-study effects were detected for several structural outcomes. Dose-response associations varied across analytical specifications and did not establish a stable optimal dose. Certainty of evidence was low for CTX-1 and very low for all other outcomes. Conclusion: Naringin showed a broad favourable preclinical signal for improving bone density, trabecular microarchitecture, and selected bone turnover markers in animal models of osteoporosis. The evidence was comparatively more robust for BMD and CTX-1, whereas heterogeneity, methodological limitations, and low certainty of evidence reduced confidence in the magnitude and reproducibility of effects across experimental settings. These findings support further investigation of naringin as a potential skeletal protective agent, with well-designed preclinical studies needed to clarify reproducibility, dose-response relationships, and translational relevance. Systematic Review Registration: identifier CRD420261419299.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.